Disc Medicine (IRON) COO trades 100 shares after option exercise under 10b5-1 plan

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Operating Officer Jonathan Yen-Wen Yu reported an option exercise and related stock sale. On July 7, 2026, he exercised stock options for 100 shares of common stock at $13.50 per share and sold 100 shares of common stock at an average price of $82.50 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he holds 54,324 shares of common stock directly and 23,747 stock options exercisable for common shares, with the option grant vesting in 48 equal monthly installments after December 29, 2022.

Insights

Equity compensation analyst

COO executes small, pre-planned option exercise and sale with modest net share reduction.

Chief Operating Officer Jonathan Yen-Wen Yu exercised stock options for 100 shares at a strike price of $13.50 and sold 100 common shares at an average of $82.50 on July 7, 2026. The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted on March 17, 2026, indicating the timing was pre-arranged rather than discretionary.

After the transactions, he directly holds 54,324 common shares and 23,747 remaining stock options expiring on December 28, 2032. The options vest in 48 equal monthly installments after December 29, 2022, so additional shares may be acquired over time as vesting continues. Given the small number of shares involved relative to his reported holdings and the use of a 10b5-1 plan, this appears as routine portfolio and compensation management rather than a shift in outlook.

Insider Trade Summary 10b5-1

Net Seller: 100 shares ($8,250)

Net Sell 3 txns

Insider Yu Jonathan Yen-Wen

Role Chief Operating Officer

Sold 100 shs ($8K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	100	$0.00	--
Exercise	Common Stock	100	$13.50	$1K
Sale	Common Stock	100	$82.50	$8K

Holdings After Transaction: Stock Option (Right to Buy) — 23,747 shares (Direct, null); Common Stock — 54,424 shares (Direct, null)

Footnotes (1)

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 100 shares Sale price: $82.50 per share Option exercise shares: 100 shares +5 more

8 metrics

Shares sold 100 shares Open-market sale of common stock on July 7, 2026 at $82.50 per share

Sale price $82.50 per share Average price for 100 common shares sold on July 7, 2026

Option exercise shares 100 shares Shares acquired via stock option exercise on July 7, 2026

Option strike price $13.50 per share Conversion or exercise price of stock option exercised for 100 shares

Common shares held after 54,324 shares Directly owned Disc Medicine common stock following reported transactions

Options held after 23,747 options Stock options (right to buy common stock) remaining after the exercise

Option expiration December 28, 2032 Expiration date of the stock option grant involved in the exercise

Vesting schedule 48 equal monthly installments Vesting pattern following December 29, 2022 for the option grant

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), underlying security, vesting

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"The shares underlying this option vest in 48 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/09/2026 - 07:35 PM Accepted by SEC EDGAR 07/09/2026 - 07:35 PM Learn about SEC filing dates

FAQ

What did Disc Medicine (IRON) COO Jonathan Yen-Wen Yu report in this Form 4?

He reported an option exercise for 100 shares of Disc Medicine common stock at $13.50 per share and an open-market sale of 100 shares at an average price of $82.50 on July 7, 2026.

How many Disc Medicine (IRON) shares does the COO hold after these transactions?

After the reported transactions, COO Jonathan Yen-Wen Yu holds 54,324 shares of Disc Medicine common stock directly and 23,747 stock options that are exercisable for common shares, according to the Form 4 data.

Were the Disc Medicine (IRON) COO’s trades made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026, indicating the trades were pre-arranged rather than opportunistic.

What are the key prices in the Disc Medicine (IRON) COO’s Form 4 transactions?

The COO exercised options at a $13.50 per-share strike price and sold 100 shares of common stock at an average price of $82.50 per share on July 7, 2026, as disclosed.

What are the terms of the Disc Medicine (IRON) stock options exercised by the COO?

The exercised option covers 100 shares of common stock at $13.50 per share, expiring on December 28, 2032. The underlying option grant vests in 48 equal monthly installments following December 29, 2022.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Jonathan Yen-Wen

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2026		M(1)		100	A	$13.5	54,424	D
Common Stock	07/07/2026		S(1)		100	D	$82.5	54,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.5	07/07/2026		M(1)			100	(2)	12/28/2032	Common Stock	100	$0	23,747	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.

2. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

	By: /s/ Rahul Khara, as Attorney-in-Fact	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)